Over the last twenty years there has been an alarming increase in isolation of Streptococcus pneumoniae strains with a reduced susceptibility not only to penicillin, but also to other betalactams and macrolides. This phenomenon justifies the great interest in new antibiotics. Cefditoren, a new aminothiazolyl oral cephalosporin, recently commercialized in Italy, is characterized by an extended activity against penicillin-resistant S. pneumoniae. The aim of this study is to evaluate the incidence of the resistance/susceptibility to various antibiotics in 1000 strains of S. pneumoniae (678 SPSS, 219 SPPI and 103 SPPR), clinically isolated during 2009. The data obtained by our in vitro study show that cefditoren is the most active agent against S. pneumoniae. In fact, the MIC90 values of 0.5 fig/ml obtained could be particularly significant in terms of therapeutic predictivity.
JohnsonDMBiedenbachDJBeachMLPfallerMAJonesRN. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. Diagn Microbiol Infect Dis2000; 37:99–105.
2.
BlasiFFarrellDJDubreuilL. Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired respiratory tract infections: the Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Diagn Microbiol Infect Dis2009; 63:302–8.
3.
StefaniSMezzatestaMLFaddaGMartinaRPalùGRossanoFTufanoMASchitoGCNicolettiG. Antibacterial activity of cefditoren against major community-acquired respiratory pathogens recently isolated in Italy. J Chemother2008; 20:561–69.
4.
Clinical and Laboratory Standards Institute, 2008 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing, 18th informational supplement, M100-S19, CLSI, Wayne, PA (2008).
5.
Clinical and Laboratory Standards Institute, 2009 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing, 19th informational supplement, M100-S19, CLSI, Wayne, PA (2009).
6.
CDC Effects of New Penicillin Susceptibility Breakpoints for Streptococcus pneumoniae - United States, 2006–2007. MMWR2008; 57:1353–55.
7.
WoodheadMBlasiFEwigS. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J2005; 26:1138–80.
8.
BurgessDSLewisJS. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther2000; 22:872–78.
9.
MazzeiTNovelliA. Cefditoren Pivoxil: Una nuova cefalosporina orale per il trattamento delle infezioni respiratorie comunitarie. Farmaci Terapia2008; XXV: 1–20.
10.
ClarkCLNagaiKDewasseBEPankuchGAEdnieLMJacobsMRAppelbaumPC. Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother2002; 50:33–41.
11.
JonesRNBiedenbachDJCrocoMABarrettMS. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Diagn Microbiol Infect Dis1998; 31:573–78.
12.
JonesRNPfallerMAJacobsMRAppelbaumPCFuchsPC. Cefditoren in vitro activity and spectrum: a review of international studies using reference methods. Diagn Microbiol Infect Dis2001; 41:1–14.
13.
SaderHSJacobsMRFritscheTR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis2007; 57:S5–S12.
14.
WellingtonKCurranMP. Spotlight on cefditoren pivoxil in bacterial infections. Treat Respir Med2005; 4:149–52.
15.
SakanoTNejihashiNFurueTKinoshitaY. Ono H, Ohta T. Changes in the drug resistance of Haemophilus influenzae and Streptococcus pneumoniae isolated between 1997 and 2006. Kansenshogaku Zasshi2009; 83:347–54.
16.
NagaiKDaviesTAJacobsMRAppelbaumPC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) la, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother2002; 46:1273–80.
17.
YamadaMWatanabeTMiyaraTBabaNSaitoJTakeuchiYOhsawaF. Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial activity. Antimicrob Agents Chemother2007; 51:3902–07.
18.
BiedenbachDJJonesRN. Update of cefditoren activity tested against community-acquired pathogens associated with infections of the respiratory tract and skin and skin structures, including recent pharmacodynamic considerations. Diagn Microbiol Infect Dis2009; 64:202–12.
19.
SaderHSJacobsMRFritscheTR. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate. Diagn Microbiol Infect Dis2007; 57(S):5–12.
20.
SeralCSuárezLRubio-CalvoC. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain. Diagn Microbiol Infect Dis2008; 62:210–15.
21.
LeeMYKoKSOhWS. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents2006; 28:14–8.
22.
SutcliffeJGrebeTTait-KamradtAWondrackL. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother1996; 40:2562–66.
23.
SeppäläHSkurnikMSoiniHRobertsMCHuovinenP. A novel erythromycin resistance methylase gene (ermTR) in Streptococcus pneumonia. Antimicrob Agents Chemother1998; 42:257–62.
24.
KlaassenCHWMoutonJW. Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E). Antimicrob Agents Chemother2005; 49:1271–78.
25.
JenkinsSGFarrelDJ. Increase in pnemococcus macrolide resistance, United States. Emerg Infect Dis2009; 15:1260–64.
26.
ReinertRR. The antimicrobial profile of Streptococcus pneumoniae. Clin Microb Infect2009; 15(S):7–11.
27.
GoosennsH. Antibiotic consumption and link to resistance. Clin Microb Infect2009; 15(S):12–15.
28.
JonesRNFritscheTRSaderHR. Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. Diagn Microbiol Infect Dis2005; 52:129–33.
29.
DeshpandeLMSaderHSDebbiaENicolettiGFaddaGJonesRN. Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001–2004). Diagn Microbiol Infect Dis2006; 54:157–64.
30.
MontagnaniFStolzuoliLZanchiACrestiSCellesiC. Antimicrobial susceptibility of Streptococcus pyogenes and Streptococcus pneumoniae: surveillance from 1993 to 2004 in Central Italy. J Chemother2006; 18:389–93.
31.
MazzariolAKoncanRBaharGCornagliaG. Susceptibilities of Streptococcus pyogenes and Streptococcus pneumoniae to macrolides and telithromycin: data from an Italian multicenter study. J Chemother2007; 19:500–7.
32.
MontagnaniFFanettiAStolzuoliLCrociLArenaFZanchiACellesiC. Pneumococcal disease in a pediatric population in a hospital of central Italy: a clinical and microbiological case series from 1992 to 2006. J Infect2008; 56:179–84.
33.
FenollARobledoOLermaMGiménezMJCebriànLCasalJAguilarLGomez-LusML. Activity of Cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter2006; 19:39–44.
34.
Pérez-TralleroEMarimónJMErcibengoaMGiménezMJCoronelPAguilarL. Antimicrobial susceptibilities of amoxicillin-non-susceptible and susceptible isolates among penicillin-non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect2007; 13:937–40.
35.
FenollAGiménezMJRobledoOAguilarLTarragóDGranizoJJMartín-HerreroJE. Influence of penicillin/amoxicillin non-susceptibility on the activity of third-generation cephalosporins against Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis2008; 27:75–80.
36.
FritscheTRBiedenbachDJJonesRN. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004–2006). J Chemother2008; 20:170–4.
37.
FenollAGiménezMJRobledoOAguilarLTarragóDGranizoJJGimenoMCoronelP. In vitro activity of oral cephalosporins against pediatric isolates of Streptococcus pneumoniae non-susceptible to penicillin, amoxicillin or erythromycin. J Chemother2008; 20:175–9.
38.
VaraldoPEMontanariMPGiovanettiE. Genetic elements responsible for erythromycin resistance in streptococci. Antimicrob Agents Chemother2009; 53:343–53.
